OR WAIT null SECS
September 05, 2023
Both companies have a focus to developing and commercializing treatments for rare diseases with a strong focus on patients and supporting communities with little to no existing therapeutic options.
September 01, 2023
Pharma's ability to continually reinvent itself will be critical in growing future business operations.
August 29, 2023
Danaher intends to acquire Abcam, a provider of life sciences assays and reagents, for $5.7 billion.
August 15, 2023
Harmony Biosciences announced a definitive agreement to acquire Zynerba Pharmaceuticals on Aug. 14, 2023.
The acquisition of the latter includes the company’s lead development asset INV-202, an oral CB1 inverse agonist which is designed to block the receptor protein CB1.
The completion of three acquisitions of Versanis Bio, Sigilon Therapeutics, and DICE Therapeutics boosts Eli Lilly and Company’s product pipeline in obesity, diabetes, and immunology.
August 11, 2023
Novartis has completed its acquisition of biopharma company Chinook Therapeutics.
August 10, 2023
The initial collaboration between the two companies began in 2017 with an extension announced in 2021.
August 07, 2023
BlueRock will be responsible for the global development and commercialization of therapeutic candidates emerging from this collaboration.
August 01, 2023
Biogen’s acquisition of Reata will grant them access to Reata’s FDA-approved treatment for Friedreich’s ataxia.